Regeneron Pharmaceuticals Inc. in Tarrytown presented its latest clinical data in early- and late-stage cancers from its oncology pipeline at the European Society for Medical Oncology (ESMO) Congress 2023 from Oct. 20 to 24 in Madrid, Spain. The presentations demonstrate the role of Libtayo® (cemiplimab) as both a monotherapy and a backbone of novel investigational combinations for various solid tumors.
“Our data presentations at ESMO underscore Regeneron’s ability to apply a deep understanding of cancer biology, genetics and the immune system to advance the development of meaningful combinations for cancer types that have high unmet need,” said Israel Lowy, senior vice president, translational and clinical oncology at Regeneron. “Notably, we are presenting the first survival data for neoadjuvant Libtayo therapy in cutaneous squamous cell carcinoma and the first results for Libtayo in combination with ubamatamab, our investigational MUC16xCD3 bispecific antibody, in recurrent ovarian cancer. Beyond ESMO, we are excited by recent progress across our oncology portfolio, including FDA Fast Track Designation for fianlimab (LAG-3) plus Libtayo in melanoma. We look forward to sharing more with the global oncology community as we deliver on our promise to improve the lives of those impacted by cancer.”
Additional presentations at ESMO included subgroup analyses of Libtayo in advanced non-small cell lung cancer, focusing on such populations as squamous cell carcinoma and patients with varying levels of PD-L1 expression.
Backed by our legacy of scientific innovation and a deep understanding of biology, genetics and the immune system, Regeneron is pursuing potential therapies across more than 30 types of solid tumors and blood cancers. Its cancer strategy is powered by cutting-edge technologies and therapies that can be flexibly combined to investigate potentially transformative treatments for patients. Oncology assets in clinical development comprise nearly half of Regeneron’s pipeline and include checkpoint inhibitors, bispecific antibodies and costimulatory bispecific antibodies. Its approved PD-1 inhibitor Libtayo serves as the backbone of many of its investigational combinations.
Regeneron is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led for 35 years by physician-scientists, its unique ability to repeatedly and consistently translate science into medicine has led to numerous FDA-approved treatments and numerous product candidates in development, almost all of which were homegrown in its laboratories. Its medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, hematologic conditions, infectious diseases and rare diseases.
